GlassScriptPhysician profile
Shabnam Gupta
NPI 1427097039
$5,783.30
in general payments reported to CMS, 2019-2025
34 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $134 · 2021: $448 · 2022: $1,074 · 2023: $1,317 · 2024: $1,127 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.99 |
| Education | $146.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,195.30 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $657.72 | 2020-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $614.45 | 2021-2025 | |
| Amgen INC. | $519.55 | 2021-2025 | Tavneos, Krystexxa, Repatha |
| Otsuka America Pharmaceutical, INC. | $423.94 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $266.67 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Mallinckrodt Hospital Products INC. | $249.28 | 2021-2025 | Acthar |
| Novo Nordisk INC | $218.39 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Travere Therapeutics, INC. | $191.82 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $158.55 | 2022-2025 | Tarpeyo |
| Abbvie INC. | $149.23 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $141.33 | 2019-2025 | Velphoro |
| Medtronic, INC. | $140.60 | 2023 | Signia |
| Ani Pharmaceuticals, INC. | $99.68 | 2024-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $88.95 | 2022-2024 | Rayaldee |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $82.70 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $82.09 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.99 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $75.88 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $67.95 | 2022-2023 | Benlysta, Jesduvroq |
| Arbor Pharmaceuticals, INC. | $38.24 | 2020-2021 | |
| Myovant Sciences INC. | $36.46 | 2022 | |
| Lilly USA, LLC | $31.91 | 2019-2025 | Mounjaro |
| Astellas Pharma US INC | $23.57 | 2024 | Veozah |
| Aurinia Pharma U.S., INC. | $17.87 | 2025 | Lupkynis |
| Azurity Pharmaceuticals, INC. | $17.80 | 2023 | Edarbi |
| Nevro Corp. | $16.82 | 2021 | |
| Shire North American Group INC | $14.96 | 2019 | |
| Daiichi Sankyo INC. | $14.58 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.16 | 2023 | |
| Amarin Pharma, INC. | $13.85 | 2021 | |
| Avion Pharmaceuticals | $13.68 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2020 | |
| Bard Peripheral Vascular, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabnam Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.